Viral Vector Manufacturing Market

Gene Therapy, Non Viral Vector and Viral Vector Manufacturing Market (6th Edition), Industry Trends and Global Forecasts, Till 2035: Distribution by Scale of Operation (Preclinical, Clinical and Commercial), Type of Vector (AAV Vectors, Adenoviral Vectors, Lentiviral Vectors, Retroviral Vectors, Plasmid DNA and Other Vectors), Application Area (Gene Therapies, Cell Therapies and Vaccines), Therapeutic Area (Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders and Other Disorders), Type of Manufacturer (In-house Manufacturers and Contract Manufacturing Organizations) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    580

  • Pages
    768

  • View Count
    54608

Table Of Contents

1. PREFACE
1.1. Viral Vector Manufacturing Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Viral and Non-Viral Gene Transfer Techniques
5.3. Viral Vectors Used in Genetically Modified Therapies
5.4. Types of Viral Vectors

5.4.1. Adeno-associated Viral Vectors
5.4.1.1. Overview
5.4.1.2. Design and Manufacturing
5.4.1.3. Advantages
5.4.1.4. Limitations

5.4.2. Adenoviral Vectors
5.4.2.1. Overview
5.4.2.2. Design and Manufacturing
5.4.2.3. Advantages
5.4.2.4. Limitations

5.4.3. Lentiviral Vectors
5.4.3.1. Overview
5.4.3.2. Design and Manufacturing
5.4.3.3. Advantages
5.4.3.4. Limitations

5.4.4. Retroviral Vectors
5.4.4.1. Overview
5.4.4.2. Design and Manufacturing
5.4.4.3. Advantages
5.4.4.4. Limitations

5.4.5. Other Viral Vectors
5.4.5.1. Alphavirus
5.4.5.2. Foamy Virus
5.4.5.3. Herpes Simplex Virus
5.4.5.4. Sendai Virus
5.4.5.5. Simian Virus
5.4.5.6. Vaccinia Virus
5.4.5.5. Chimeric Viral Vectors

5.5. Types of Non-Viral Vectors
5.5.1. Plasmid DNA
5.5.2. Liposomes, Lipoplexes and Polyplexes
5.5.3. Oligonucleotides
5.5.4. Other Non-Viral Vectors

5.6. Gene Delivery using Non-Viral Vectors
5.6.1. Biolistic Methods
5.6.2. Electroporation
5.6.3. Receptor Mediated Gene Delivery
5.6.4. Gene Activated Matrix (GAM)

5.7. Applications of Viral and Non-Viral Vectors
5.7.1. Cell and Gene Therapy
5.7.2. Vaccine

5.8. Current / Ongoing Trends in Vector Development / Manufacturing
5.8.1. Vector Engineering
5.8.2. Cargo Engineering

5.9. Vector Manufacturing
5.9.1. Types of Vector Manufacturers
5.9.2. Viral Vector Manufacturing Processes
5.9.2.1 Vector Production
5.9.2.2. Adherent and Suspension Cultures
5.9.2.3. Unit Process Versus Multiple Parallel Processes

5.9.2.4. Cell Culture Systems for Production of Viral Vectors
5.9.2.4.1. Small Scale / Laboratory Scale Cell Culture Systems
5.9.2.4.2. Large Scale Cell Culture Systems
5.9.2.4.2.1. Stirred Tank Reactor Systems
5.9.2.4.2.2. Fixed Bed Reactors / Packed Bed Reactors
5.9.2.4.2.3. Wave Bioreactor Systems

5.9.2.5. Serum-Containing versus Serum-Free Media

5.9.3. Bioprocessing of Viral Vectors
5.9.3.1. AAV Vector Production
5.9.3.2. Adenoviral Vector Production
5.9.3.3. Lentiviral Vector Production
5.9.3.4. γ -Retroviral Vector Production

5.9.4. Key Challenges Associated with Vector Manufacturing

5.10. Future Perspectives

6. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Product Manufactured
6.2.5. Analysis by Location of Vector Manufacturing Facility
6.2.6. Analysis by Type of Manufacturer
6.2.7. Analysis by Scale of Operation
6.2.8. Analysis by Location of Headquarters and Scale of Operation
6.2.9. Analysis by Type of Viral Vector Manufactured
6.2.10. Analysis by Scale of Operation and Type of Viral Vector Manufactured
6.2.11. Analysis by Application Area
6.2.12. Information on Production Capacity

7. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Company Size and Location of Headquarters
7.2.5. Analysis by Type of Product Manufactured
7.2.6. Analysis by Location of Plasmid DNA Manufacturing Facility
7.2.7. Analysis by Type of Manufacturer
7.2.8. Analysis by Scale of Operation
7.2.9. Analysis by Application Area
7.2.10. Information on Production Capacity

8. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Location of Vector Manufacturing Facility (Region)
8.2.3. Analysis by Location of Vector Manufacturing Facility (Country)
8.2.3. Analysis by Type of Manufacturer
8.2.4. Analysis by Scale of Operation
8.2.5. Analysis by Type of Vector Manufactured
8.2.6. Analysis by Scale of Operation and Type of Vector Manufactured
8.2.7. Analysis by Application Area

9. VECTOR AND GENE THERAPY MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Vector and Gene Therapy Manufacturing Technologies: Overall Market Landscape
9.2.1. Analysis by Type of Technology
9.2.2. Analysis by Purpose of Technology
9.2.3. Analysis by Scale of Operation
9.2.4. Analysis by Type of Vector
9.2.5. Analysis by Application Area
9.2.6. Most Active Players: Analysis by Number of Technologies

9.3. Concluding Remarks

10. COMPANY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Methodology and Key Parameters
10.3. Vector and Gene Therapy In-House Manufacturers: Company Competitiveness Analysis
10.3.1. Players based in North America
10.3.2. Players based in Europe
10.3.3. Players based in Asia-Pacific and Rest of the World

10.4. Vector and Gene Therapy Contract Manufacturing Organizations: Company Competitiveness Analysis
10.4.1. Players based in North America
10.4.2. Players based in Europe
10.4.3. Players based in Asia-Pacific and Rest of the World

10.5. Vector and Gene Therapy In-house Manufacturers and Contract Manufacturing Organizations: Company Competitiveness Analysis
10.5.1. Players based in North America
10.5.2. Players based in Europe
10.5.3. Players based in Asia-Pacific and Rest of the World

11. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
11.1. Chapter Overview
11.2. Key Players
11.2.1. Advanced BioScience Laboratories
11.2.1.1. Company Overview
11.2.1.2. Vector Manufacturing Related Capabilities
11.2.1.3. Recent Developments and Future Outlook

11.2.2. Catalent Biologics
11.2.2.1. Company Overview
11.2.2.2. Financial Information
11.2.2.3. Vector Manufacturing Related Capabilities
11.2.2.4. Recent Developments and Future Outlook

11.2.3. Charles River Laboratories
11.2.3.1. Company Overview
11.2.3.2. Financial Information
11.2.3.3. Vector Manufacturing Related Capabilities
11.2.3.4. Recent Developments and Future Outlook

11.2.4. Thermo Fisher Scientific
11.2.4.1. Company Overview
11.2.4.2. Financial Information
11.2.4.3. Vector Manufacturing Related Capabilities
11.2.4.4. Recent Development and Future Outlook

11.2.5. VectorBuilder
11.2.5.1. Company Overview
11.2.5.2. Financial Information
11.2.5.3. Vector Manufacturing Related Capabilities
11.2.5.4. Recent Developments and Future Outlook

11.3. Other Key Players
11.3.1. AGC Biologics
11.3.1.1. Company Overview
11.3.1.2. Vector Manufacturing Related Capabilities

11.3.2. Aldevron
11.3.2.1. Company Overview
11.3.2.2. Vector Manufacturing Related Capabilities

11.3.3. Matica Biotechnology
11.3.3.1. Company Overview
11.3.3.2. Vector Manufacturing Related Capabilities

11.3.4. Resilience
11.3.4.1. Company Overview
11.3.4.2. Vector Manufacturing Related Capabilities

12. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
12.1. Chapter Overview
12.2. Key Players
12.2.1. Lonza
12.2.1.1. Company Overview
12.2.1.2. Financial Information
12.2.1.3. Vector Manufacturing Related Capabilities
12.2.1.4. Recent Developments and Future Outlook

12.2.2. Touchlight
12.2.2.1. Company Overview
12.2.2.2. Vector Manufacturing Related Capabilities
12.2.2.3. Recent Developments and Future Outlook

12.3. Other Key Players
12.3.1. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
12.3.1.1. Company Overview
12.3.1.1. Vector Manufacturing Related Capabilities

12.3.2. Biovian
12.3.2.1. Company Overview
12.3.2.2. Vector Manufacturing Related Capabilities

12.3.3. Celonic
12.3.3.1. Company Overview
12.3.3.2. Vector Manufacturing Related Capabilities

12.3.4. Centre for Process Innovation
12.3.4.1. Company Overview
12.3.4.2. Vector Manufacturing Related Capabilities

12.3.5. CEVEC Pharmaceuticals
12.3.5.1. Company Overview
12.3.5.2. Vector Manufacturing Related Capabilities

12.3.6. NorthX Biologics
12.3.6.1. Company Overview
12.3.6.2. Vector Manufacturing Related Capabilities

12.3.7. Novartis
12.3.7.1. Company Overview
12.3.7.2. Vector Manufacturing Related Capabilities

12.3.8. Oxford BioMedica
12.3.8.1. Company Overview
12.3.8.2. Vector Manufacturing Related Capabilities

12.3.9. Sanofi
12.3.9.1. Company Overview
12.3.9.2. Vector Manufacturing Related Capabilities

13. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
13.1. Chapter Overview
13.2. Key Players
13.2.1. CoJourney
13.2.1.1. Company Overview
13.2.1.2. Vector Manufacturing Related Capabilities
13.2.1.3. Recent Developments and Future Outlook

13.2.2. Esco Aster
13.2.2.1. Company Overview
13.2.2.2. Vector Manufacturing Related Capabilities
13.2.2.3. Recent Developments and Future Outlook

13.2.3. Wuxi AppTec
13.2.3.1. Company Overview
13.2.3.2. Financial Information
13.2.3.3. Vector Manufacturing Related Capabilities
13.2.3.4. Recent Developments and Future Outlook

13.3. Other Key Players
13.3.1. Altruist Biotechnology
13.3.1.1. Company Overview
13.3.1.2. Vector Manufacturing Related Capabilities

13.3.2. Jiangsu Puxin Biopharmaceutical
13.3.2.1. Company Overview
13.3.2.2. Vector Manufacturing Related Capabilities

13.3.3. Nikon CeLL innovation
13.3.3.1. Company Overview
13.3.3.2. Vector Manufacturing Related Capabilities

14. PORTER’S FIVE FORCES ANALYSIS
14.1 Chapter Overview
14.2. Methodology and Assumptions
14.3. Key Parameters
14.3.1. Threats of New Entrants
14.3.2. Bargaining Power of Suppliers
14.3.3. Bargaining Power of Buyers
14.3.4. Threats of Substitute Products
14.3.5. Rivalry Among Existing Competitors

14.4. Concluding Remarks

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Vector and Gene Therapy Manufacturing: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Scale of Operation
15.3.4. Analysis by Type of Vector Manufactured
15.3.5. Analysis by Therapeutic Area
15.3.6. Analysis by Application Area
15.3.7. Most Active Players: Analysis by Number of Partnerships

15.3.8. Analysis by Geography
15.3.8.1. Local and International Agreements
15.3.8.2. Intercontinental and Intracontinental Agreements

15.4. Other Collaborations

16. RECENT EXPANSIONS
16.1. Chapter Overview
16.2. Expansions Models
16.3. Vector and Gene Therapy Manufacturing: Recent Expansions
16.3.1. Analysis by Year of Expansion
16.3.2. Analysis by Type of Expansion
16.3.3. Analysis by Year and Type of Expansion
16.3.4. Most Active Players: Analysis by Number of Expansions
16.3.5. Most Active Players: Analysis by Amount Invested
16.3.6. Analysis by Type of Manufacturing Facility
16.3.7. Analysis by Scale of Operation
16.3.8. Analysis by Type of Vector Manufactured
16.3.9. Analysis by Application Area

16.3.10. Analysis by Geography
16.3.10.1. Intercontinental and Intracontinental Expansions
16.3.10.2. Analysis by Location of Expansion

17. STRATEGIC PARTNER ANALYSIS
17.1. Chapter Overview
17.2. Methodology and Key Parameters
17.3. Strategic Partner Analysis: Viral Vector based Therapy Developers
17.3.1. AAV Vector based Therapy Developers
17.3.1.1. Most Likely Partners
17.3.1.2. Likely Partners
17.3.1.3. Less Likely Partners
17.3.1.4. Least Likely Partners

17.3.2. Adenoviral Vector based Therapy Developers
17.3.2.1. Most Likely Partners
17.3.2.2. Likely Partners
17.3.2.3. Less Likely Partners
17.3.2.4. Least Likely Partners

17.3.3. Lentiviral Vector based Therapy Developers
17.3.3.1. Most Likely Partners
17.3.3.2. Likely Partners
17.3.3.3. Less Likely Partners
17.3.3.4. Least Likely Partners

17.3.4. Retroviral Vector based Therapy Developers
17.3.4.1. Most Likely Partners
17.3.4.2. Likely Partners
17.3.4.3. Less Likely Partners
17.3.4.4. Least Likely Partners

17.3.5. Other Viral Vector based Therapy Developers
17.3.5.1. Most Likely Partners
17.3.5.2. Likely Partners
17.3.5.3. Less Likely Partners
17.3.5.4. Least Likely Partners

17.4. Strategic Partner Analysis: Viral Vector based Purification Product Developers
17.5. Methodology and Key Parameters
17.5.1. Opportunities for AAV based Purification Product Developers
17.5.1.1. Most Likely Partners
17.5.1.2. Likely Partners

17.5.2. Opportunities for Adenoviral Vector based Purification Product Developers
17.5.2.1. Most Likely Partners
17.5.2.2. Likely Partners

17.5.3. Opportunities for Lentiviral Vector based Purification Product Developers
17.5.3.1. Most Likely Partners
17.5.3.2. Likely Partners

17.5.4. Opportunities for Retroviral Vector based Purification Product Developers
17.5.4.1. Most Likely Partners
17.5.4.2. Likely Partners

17.5.5. Opportunities for Other Viral Vector based Purification Product Developers
17.5.5.1. Most Likely Partners
17.5.5.2. Likely Partners

18. EMERGING VECTORS
18.1. Chapter Overview
18.1.1. Alphavirus based Vectors
18.1.2. Anc80 based Vectors
18.1.3. Bifidobacterium longum based Vectors
18.1.4. Cytomegalovirus based Vectors
18.1.5. Listeria monocytogenes based Vectors
18.1.6. Minicircle DNA based Vectors
18.1.7. Myxoma Virus based Vectors
18.1.8. Self-Complementary Vectors
18.1.9. Sendai Virus based Vectors
18.1.10. Sleeping Beauty Transposons
18.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors
18.1.12. Chimeric Viral Vectors

19. KEY INSIGHTS
19.1. Chapter Overview
19.2. Vector and Gene Therapy Manufacturers: Key Insights
19.2.1. Analysis by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
19.2.2. Analysis by Type of Vector Manufactured and Company Size

19.2.3. Analysis by Type of Organization and Geography
19.2.3.1. Contract Manufacturing Organizations
19.2.3.2. In-House Manufacturers
19.2.3.3. In-House and Contract Manufacturing Organizations

19.2.4. Analysis by Type of Vector Manufactured and Location of Headquarters
19.2.4.1. AAV Vector Manufacturers
19.2.4.2. Adenoviral Vector Manufacturers
19.2.4.3. Lentiviral Vector Manufacturers
19.2.4.4. Retroviral Vector Manufacturers
19.2.4.5. Plasmid DNA Manufacturers

20. COST PRICE ANALYSIS
20.1. Chapter Overview
20.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
20.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models
20.3.1. Pricing Models Based on Expert Opinions
20.3.2. Pricing Models Based on Manufacturing Cost
20.3.2.1. Pricing Models Based on Technology Used
20.3.2.2. Pricing Models Based on Scale of Operation
20.3.2.3. Pricing Models Based on Type of Client

20.3.3. Prices of Different Types of Vectors

20.4. Concluding Remarks

21. OUTSOURCING: GO / NO-GO FRAMEWORK
21.1. Chapter Overview
21.2. Outsourcing: Go / No-Go Framework
21.3. Vector and Gene Therapy Manufacturers Outsourcing: Go / No-Go Framework
21.3.1. Key Parameters and Assumptions
21.3.2. Methodology
21.3.3. Results and Interpretations
21.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
21.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
21.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies

22. CAPACITY ANALYSIS
22.1. Chapter Overview
22.2. Methodology and Key Assumptions
22.3. Viral Vector and Plasmid DNA Manufacturing: Global Installed Capacity
22.4. Viral Vector Manufacturing: Global Installed Capacity
22.4.1. Analysis by Company Size
22.4.2. Analysis by Scale of Operation
22.4.3. Analysis by Location of Headquarters (Region)
22.4.4. Analysis by Location of Manufacturing Facility

22.5. Plasmid DNA Manufacturing: Global Installed Capacity
22.5.1. Analysis by Company Size
22.5.2. Analysis by Scale of Operation
22.4.3. Analysis by Location of Headquarters (Region)
22.5.4. Analysis by Location of Manufacturing Facility

22.6. Concluding Remarks

23. DEMAND ANALYSIS
23.1. Chapter Overview
23.2. Assumptions and Methodology
23.3. Global Demand for Viral Vectors and Plasmid DNA, 2023-2035
23.4. Global Clinical Demand for Viral Vectors and Plasmid DNA, 2023-2035
23.4.1. Analysis by Type of Vector
23.4.2. Analysis by Type of Therapy
23.4.3. Analysis by Therapeutic Area
23.4.4. Analysis by Geography

23.5. Global Commercial Demand for Viral Vectors and Plasmid DNA, 2023-2035
23.5.1. Analysis by Type of Vector
23.5.2. Analysis by Type of Therapy
23.5.3. Analysis by Therapeutic Area
23.5.4. Analysis by Geography

23.6. Demand and Supply Analysis
23.6.1. Scenario 1
23.6.2. Scenario 2
23.6.3. Scenario 3

24. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
24.1. Chapter Overview
24.2. Market Drivers
24.3. Market Restraints
24.4. Market Opportunities
24.5. Market Challenges
24.6. Conclusion

25. GLOBAL VIRAL VECTOR, NON-VIRAL VECTOR AND GENE THERAPY MANUFACTURING MARKET
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Global Viral Vector and Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.1. Scenario Analysis

25.4. Key Market Segmentations
25.5. Dynamic Dashboard

26. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY SCALE OF OPERATION
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Preclinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.4. Clinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.5. Commercial Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.6. Data Triangulation and Validation

27. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE OF VECTOR
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. AAV Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.4. Adenoviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.5. Lentiviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.6. Retroviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.7. Plasmid DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.8. Other Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.9. Data Triangulation and Validation

28. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION AREA
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Gene Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.4. Cell Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.5. Vaccine Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.6. Data Triangulation and Validation

29. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY THERAPEUTIC AREA
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.4. Rare Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.5. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.6. Sensory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.7. Metabolic Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.8. Musculoskeletal Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.9. Blood Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.10. Immunological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.11. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.12. Data Triangulation and Validation

30. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. In-house Manufacturers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.4. Contract Manufacturing Organizations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.5. Data Triangulation and Validation

31. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.5. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.6. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.7. Latin America and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.8. Data Triangulation and Validation

32. SURVEY ANALYSIS
32.1. Chapter Overview
32.2. Analysis by Seniority Level of Respondents
32.3. Analysis by Type of Manufacturer
32.4. Analysis by Scale of Operation
32.5. Analysis by Type of Vector Manufactured

33. CONCLUDING REMARKS

34. EXECUTIVE INSIGHTS
34.1. Chapter Overview
34.2. HALIX
34.2.1. Company Snapshot
34.2.2. Interview Transcript: Business Developer

34.3. Batavia Biosciences
34.3.1. Company Snapshot
34.3.2. Interview Transcript: Chief Executive Officer and President

34.4. CEVEC Pharmaceuticals
34.4.1. Company Snapshot
34.4.2. Interview Transcript: Chief Executive Officer and Chief Scientific Officer

34.5. Delphi Genetics
34.5.1. Company Snapshot
34.5.2. Interview Transcript: Former Executive and Scientific Director

34.6. Clean Cells
34.6.1. Company Snapshot
34.6.2. Interview Transcript: Co-Founder / President, Former Business Development Manager and Head of Gene Therapy

34.7. Novasep
34.7.1. Company Snapshot
34.7.2. Interview Transcript: Former President of Biopharma Business Unit

34.8. Amsterdam BioTherapeutics Unit
34.8.1. Organization Snapshot
34.8.2. Interview Transcript: Former Director

34.9. Massachusetts General Hospital
34.9.1. Organization Snapshot
34.9.2. Interview Transcript: Director

34.10. University of Nantes
34.10.1. Organization Snapshot
34.10.2. Interview Transcript: Scientific Director

34.11. CJ PARTNERS
34.11.1. Company Snapshot
34.11.2. Interview Transcript: Managing Director

34.12. ACGT
34.12.1. Company Snapshot
34.12.2. Interview Transcript: Scientific Director

34.13. Polypus Transfection
34.13.1. Company Snapshot
34.13.2. Interview Transcript: Director of Marketing and Technical Support

34.14. Richter-Helm BioLogics
34.14.1. Company Snapshot
34.14.2. Interview Transcript: Senior Manager Business Development

34.15. Plasmid Factory
34.15.1. Company Snapshot
34.15.2. Interview Transcript: Project Manager and Former Marketing Manager

34.16. Waisman Biomanufacturing
34.16.1. Company Snapshot
34.16.2. Interview Transcript: Business Development Manager

34.17. EFS-West Biotherapy
34.17.1. Company Snapshot
34.17.2. Interview Transcript: ATMP Key Account Manager

34.18. GEG Tech
34.18.1. Company Snapshot
34.18.2. Interview Transcript: R&D Leader

34.19. VIVEBiotech
34.19.1. Company Snapshot
34.19.2. Interview Transcript: Head of Marketing and Technology Development

34.20. Independent Consultant
34.20.1. Interview Transcript 

35. APPENDIX 1: TABULATED DATA

36. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape of Viral Vector and Gene Therapy Manufacturers (Industry Players)
Figure 4.2 Executive Summary: Market Landscape of Plasmid DNA and Gene Therapy Manufacturers (Industry Players)
Figure 4.3 Executive Summary: Market Landscape of Vector and Gene Therapy Manufacturers (Non-Industry Players)
Figure 4.4 Executive Summary: Market Landscape of Vector and Gene Therapy Manufacturing Technologies
Figure 4.5 Executive Summary: Partnerships and Collaborations
Figure 4.6 Executive Summary: Recent Expansions
Figure 4.7 Executive Summary: Capacity Analysis
Figure 4.8 Executive Summary: Demand Supply Analysis
Figure 4.9 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 5.2 Vector Production: Types of Manufacturers
Figure 5.3 Viral Vectors: Process of Manufacturing
Figure 6.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 6.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 6.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Figure 6.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Figure 6.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 6.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Figure 6.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Figure 6.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 6.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 6.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Figure 6.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Figure 6.12 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Viral Vector Manufactured
Figure 6.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 7.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 7.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 7.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Figure 7.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Figure 7.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 7.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 7.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Region)
Figure 7.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Country)
Figure 7.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 7.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 7.11 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 8.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Year of Establishment
Figure 8.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Figure 8.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Figure 8.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer
Figure 8.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Figure 8.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 8.7 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Figure 8.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 9.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 9.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 9.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Figure 9.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector
Figure 9.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 9.6 Most Active Players: Distribution by Number of Technologies
Figure 10.1 Company Competitiveness Analysis: In-House Manufacturers based in North America
Figure 10.2 Company Competitiveness Analysis: In-House Manufacturers based in Europe
Figure 10.3 Company Competitiveness Analysis: In-House Manufacturers based in Asia-Pacific and Rest of the World
Figure 10.4 Company Competitiveness Analysis: Contract Manufacturing Organizations based in North America
Figure 10.5 Company Competitiveness Analysis: Contract Manufacturing Organizations based in Europe
Figure 10.6 Company Competitiveness Analysis: Contract Manufacturing Organizations based in Asia-Pacific and Rest of the World
Figure 10.7 Company Competitiveness Analysis: In-House Manufacturers and Contract Manufacturing Organizations based in North America
Figure 10.8 Company Competitiveness Analysis: In-House Manufacturers and Contract Manufacturing Organizations based in Europe
Figure 10.9 Company Competitiveness Analysis: In-House Manufacturers and Contract Manufacturing Organizations based in Asia-Pacific and Rest of the World
Figure 11.1 Catalent Biologics: Annual Revenues, FY 2018 - 9M FY 2023 (USD Billion)
Figure 11.2 Charles River Laboratories: Annual Revenues, FY 2018 - H1 FY 2023 (USD Billion)
Figure 11.3 Thermo Fisher Scientific: Annual Revenues, FY 2018 – 9M FY 2023 (USD Billion)
Figure 12.1 Lonza: Annual Revenues, FY 2018 – H1 FY 2023 (CHF Billion)
Figure 13.1 Wuxi AppTec: Annual Revenues, FY 2018 - H1 FY 2023 (RMB Billion)
Figure 14.1 Porter’s Five Forces
Figure 14.2 Porter’s Five Forces: Harvey Ball Analysis
Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Vector Manufactured
Figure 15.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.6 Partnerships and Collaborations: Distribution by Application Area
Figure 15.7 Most Active Players: Distribution by Number of Partnerships
Figure 15.8 Partnerships and Collaborations: Local and International Agreements
Figure 15.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 16.1 Recent Expansions: Cumulative Year-wise Trend, 2015-2023
Figure 16.2 Recent Expansions: Distribution by Type of Expansion
Figure 16.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 16.4 Most Active Players: Distribution by Number of Expansions
Figure 16.5 Most Active Players: Distribution by Amount Invested
Figure 16.6 Recent Expansions: Distribution by Type of Manufacturing Facility
Figure 16.7 Recent Expansions: Distribution by Scale of Operation
Figure 16.8 Recent Expansions: Distribution by Type of Vector Manufactured
Figure 16.9 Recent Expansions: Distribution by Application Area
Figure 16.10 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 16.11 Recent Expansions: Distribution by Location of Expansion
Figure 19.1 Vector and Gene Therapy Manufacturers: Distribution by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Figure 19.2 Vector and Gene Therapy Manufacturers: Distribution by Type of Vector Manufactured and Company Size
Figure 19.3 Vector and Gene Therapy Contract Manufacturing Organizations: Distribution by Geography
Figure 19.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Geography
Figure 19.5 Vector and Gene Therapy In-House and Contract Manufacturing Organizations: Distribution by Geography
Figure 19.6 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 19.7 Adenoviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 19.8 Lentiviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 19.9 Retroviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 19.10 Plasmid DNA Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 20.1 Viral Vector and Plasmid DNA based Therapies Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 21.1 Outsourcing: Go / No-Go Framework
Figure 21.2 Outsourcing: Go / No-Go Framework Methodology
Figure 21.3 Outsourcing: Go / No-Go Framework for Vector and Gene Therapy Manufacturers
Figure 21.4 Vector and Gene Therapy Manufacturers: Benchmarking of Small Companies
Figure 21.5 Vector and Gene Therapy Manufacturers: Benchmarking of Mid-sized Companies
Figure 21.6 Vector and Gene Therapy Manufacturers: Benchmarking of Large Companies
Figure 22.1 Global Installed Viral Vectors Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 22.2 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 22.3 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Figure 22.4 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 22.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 22.6 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Operation (in Liters)
Figure 22.7 Global Installed Viral Vector Manufacturing Capacity: Distribution by Location of Headquarters (Region) (in Liters)
Figure 22.8 Global Installed Viral Vector Manufacturing Capacity: Distribution by Location of Manufacturing Facility (in Liters)
Figure 22.9 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 22.10 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 22.11 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation (in Liters)
Figure 22.12 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Headquarters (Region) (in Liters)
Figure 22.13 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facility (in Liters)
Figure 23.1 Global Demand for Viral Vector and Plasmid DNA, 2023-2035 (Thousand Patients)
Figure 23.2 Clinical Demand for Viral Vector and Plasmid DNA, 2023-2035 (Thousand Patients)
Figure 23.3 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Figure 23.4 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 23.5 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 23.6 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geography (Thousand Patients)
Figure 23.7 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Figure 23.8 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Figure 23.9 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 23.10 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 23.11 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geography (Thousand Patients)
Figure 23.12 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2023-2035
Figure 23.13 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2023-2035
Figure 23.14 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2023-2035
Figure 24.1 Market Drivers
Figure 24.2 Market Restraints
Figure 24.3 Market Opportunities
Figure 24.4 Market Challenges
Figure 25.1 Global Viral Vector and Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 25.2 Global Viral Vector and Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
Figure 25.3 Global Viral Vector and Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
Figure 26.1 Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 26.2 Viral Vector and Plasmid DNA Manufacturing Market for Clinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 26.3 Viral Vector and Plasmid DNA Manufacturing Market for Commercial Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 27.1 Viral Vector and Plasmid DNA Manufacturing Market for AAV Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 27.2 Viral Vector and Plasmid DNA Manufacturing Market for Adenoviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 27.3 Viral Vector and Plasmid DNA Manufacturing Market for Lentiviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 27.4 Viral Vector and Plasmid DNA Manufacturing Market for Retroviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 27.5 Viral Vector and Plasmid DNA Manufacturing Market for Plasmid DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 27.6 Viral Vector and Plasmid DNA Manufacturing Market for Other Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 28.1 Viral Vector and Plasmid DNA Manufacturing Market for Gene Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 28.2 Viral Vector and Plasmid DNA Manufacturing Market for Cell Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 28.3 Viral Vector and Plasmid DNA Manufacturing Market for Vaccine Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.1 Viral Vector and Plasmid DNA Manufacturing Market for Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.2 Viral Vector and Plasmid DNA Manufacturing Market for Rare Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.3 Viral Vector and Plasmid DNA Manufacturing Market for Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.4 Viral Vector and Plasmid DNA Manufacturing Market for Sensory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.5 Viral Vector and Plasmid DNA Manufacturing Market for Metabolic Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.6 Viral Vector and Plasmid DNA Manufacturing Market for Musculoskeletal Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.7 Viral Vector and Plasmid DNA Manufacturing Market for Blood Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.8 Viral Vector and Plasmid DNA Manufacturing Market for Immunological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 29.9 Viral Vector and Plasmid DNA Manufacturing Market for Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 30.1 Viral Vector and Plasmid DNA Manufacturing Market for In-house Manufacturers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 30.2 V iral Vector and Plasmid DNA Manufacturing Market for Contract Manufacturing Organizations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 31.1 Viral Vector and Plasmid DNA Manufacturing Market in North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 31.2 Viral Vector and Plasmid DNA Manufacturing Market in Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 31.3 Viral Vector and Plasmid DNA Manufacturing Market in Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 31.4 Viral Vector and Plasmid DNA Manufacturing Market in Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 31.5 Viral Vector and Plasmid DNA Manufacturing Market in Latin America and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 32.1 Survey Analysis: Distribution by Type of Organization
Figure 32.2 Survey Analysis: Distribution by Location of Organization
Figure 32.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 32.4 Survey Analysis: Distribution by Type of Manufacturer
Figure 32.5 Survey Analysis: Distribution by Scale of Operation
Figure 32.6 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 33.1 Concluding Remarks: Market Landscape of Viral Vector and Gene Therapy Manufacturers (Industry Players)
Figure 33.2 Concluding Remarks: Market Landscape of Plasmid DNA and Gene Therapy Manufacturers (Industry Players)
Figure 33.3 Concluding Remarks: Market Landscape of Vector and Gene Therapy Manufacturers (Non-Industry Players)
Figure 33.4 Concluding Remarks: Market Landscape of Vector and Gene Therapy Manufacturing Technologies
Figure 33.5 Concluding Remarks: Partnerships and Collaborations
Figure 33.6 Concluding Remarks: Recent Expansions
Figure 33.7 Concluding Remarks: Capacity Analysis
Figure 33.8 Concluding Remarks: Demand Supply Analysis
Figure 33.9 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 5.1 Key Features of Viral Vectors
Table 5.2 Key Features of Small-scale Cell Culture Systems
Table 6.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 6.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Vector Manufacturing Facility, Scale of Operation and Type of Manufacturer
Table 6.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Vector Manufactured
Table 6.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 6.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 7.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 7.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facility, Type of Manufacturer and Scale of Operation
Table 7.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 7.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 8.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 8.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Operation
Table 8.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 8.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 9.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 11.1 Viral Vectors and Plasmid DNA Production in North America: List of Profiled Companies
Table 11.2 Advanced BioScience Laboratories: Company Snapshot
Table 11.3 Advanced BioScience Laboratories: Vector Manufacturing Related Capabilities
Table 11.4 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 11.5 Catalent Biologics: Company Snapshot
Table 11.6 Catalent Biologics: Vector Manufacturing Related Capabilities
Table 11.7 Catalent Biologics: Recent Developments and Future Outlook
Table 11.8 Charles River Laboratories: Company Snapshot
Table 11.9 Charles River Laboratories: Vector Manufacturing Related Capabilities
Table 11.10 Charles River Laboratories: Recent Developments and Future Outlook
Table 11.11 Thermo Fisher Scientific: Company Snapshot
Table 11.12 Thermo Fisher Scientific: Vector Manufacturing Related Capabilities
Table 11.13 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 11.14 VectorBuilder: Company Snapshot
Table 11.15 VectorBuilder: Vector Manufacturing Related Capabilities
Table 11.16 VectorBuilder: Recent Developments and Future Outlook
Table 11.17 AGC Biologics: Company Snapshot
Table 11.18 AGC Biologics: Vector Manufacturing Related Capabilities
Table 11.19 Aldevron: Company Snapshot
Table 11.20 Aldevron: Vector Manufacturing Related Capabilities
Table 11.21 Matica Biotechnology: Company Snapshot
Table 11.22 Matica Biotechnology: Vector Manufacturing Related Capabilities
Table 11.23 Resilience: Company Snapshot
Table 11.24 Resilience: Vector Manufacturing Related Capabilities
Table 12.1 Viral Vectors and Plasmid DNA Production in Europe: List of Profiled Companies
Table 12.2 Lonza: Company Snapshot
Table 12.3 Lonza: Vector Manufacturing Related Capabilities
Table 12.4 Lonza: Recent Developments and Future Outlook
Table 12.5 Touchlight: Company Snapshot
Table 12.6 Touchlight: Vector Manufacturing Related Capabilities
Table 12.7 Touchlight: Recent Developments and Future Outlook
Table 12.8 BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech): Company Snapshot
Table 12.8 BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech): Vector Manufacturing Related Capabilities
Table 12.9 Biovian: Company Snapshot
Table 12.9 Biovian: Vector Manufacturing Related Capabilities
Table 12.10 Celonic: Company Snapshot
Table 12.11 Celonic: Vector Manufacturing Related Capabilities
Table 12.12 Centre for Process Innovation: Company Snapshot
Table 12.13 Centre for Process Innovation: Vector Manufacturing Related Capabilities
Table 12.14 CEVEC Pharmaceuticals: Company Snapshot
Table 12.25 CEVEC Pharmaceuticals: Vector Manufacturing Related Capabilities
Table 12.16 NorthX Biologics: Company Snapshot
Table 12.17 NorthX Biologics: Vector Manufacturing Related Capabilities
Table 12.18 Novartis: Company Snapshot
Table 12.19 Novartis: Vector Manufacturing Related Capabilities
Table 12.20 Oxford BioMedica: Company Snapshot
Table 12.21 Oxford BioMedica: Vector Manufacturing Related Capabilities
Table 12.22 Sanofi: Company Snapshot
Table 12.23 Sanofi: Vector Manufacturing Related Capabilities
Table 13.1 Viral Vectors and Plasmid DNA Production in Asia-Pacific: List of Profiled Companies
Table 13.2 CoJourney: Company Snapshot
Table 13.3 CoJourney: Vector Manufacturing Related Capabilities
Table 13.4 CoJourney: Recent Developments and Future Outlook
Table 13.5 Esco Aster: Company Snapshot
Table 13.6 Esco Aster: Vector Manufacturing Related Capabilities
Table 13.7 Esco Aster: Recent Developments and Future Outlook
Table 13.8 Wuxi AppTec: Company Snapshot
Table 13.9 Wuxi AppTec: Vector Manufacturing Related Capabilities
Table 13.10 Wuxi AppTec: Recent Developments and Future Outlook
Table 13.11 Altruist Biotechnology: Company Snapshot
Table 13.12 Altruist Biotechnology: Vector Manufacturing Related Capabilities
Table 13.13 Jiangsu Puxin Biopharmaceutical: Company Snapshot
Table 13.14 Jiangsu Puxin Biopharmaceutical: Vector Manufacturing Related Capabilities
Table 13.15 Nikon CeLL innovation: Company Snapshot
Table 13.15 Nikon CeLL innovation: Vector Manufacturing Related Capabilities
Table 15.1 Vector and Gene Therapy Manufacturing: List of Partnerships
Table 15.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships
Table 16.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions
Table 16.2 Vector and Gene Therapy Manufacturing: Information on Type of Manufacturing Facility
Table 16.3 Vector and Gene Therapy Manufacturing: Information on Scale of Operation, Type of Vector Manufactured and Application Area
Table 17.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 17.2 AAV Vector-based Therapy Developers: Likely Partners
Table 17.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 17.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 17.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 17.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 17.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 17.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 17.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 17.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 17.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 17.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 17.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 17.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 17.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 17.16 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 17.17 Other Viral Vector-based Therapy Developers: Likely Partners
Table 17.18 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 17.19 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 17.20 AAV Vector Purification Product Manufacturers: Most Likely Partners
Table 17.21 AAV Vector Purification Product Manufacturers: Likely Partners
Table 17.22 Adenoviral Vector Purification Product Manufacturers: Most Likely Partners
Table 17.23 Adenoviral Vector Purification Product Manufacturers: Likely Partners
Table 17.24 Lentiviral Vector Purification Product Manufacturers: Most Likely Partners
Table 17.25 Lentiviral Vector Purification Product Manufacturers: Likely Partners
Table 17.26 Retroviral Vector Purification Product Manufacturers: Most Likely Partners
Table 17.27 Retroviral Vector Purification Product Manufacturers: Likely Partners
Table 17.28 Other Viral Vector Purification Product Manufacturers: Most Likely Partners
Table 17.29 Other Viral Vector Purification Product Manufacturers: Likely Partners
Table 20.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 20.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 22.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 22.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 22.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 22.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 23.1. Global Annual Demand for Viral Vectors Manufacturing, 2023-2035 (1020 vg)
Table 23.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2023-2035 (1020 vg)
Table 23.3 Global Viral Vector Manufacturing Annual Supply (Scenario 2), 2023-2035 (1020 vg)
Table 23.4 Global Viral Vector Manufacturing Annual Supply (Scenario 3), 2023-2035 (1020 vg)
Table 25.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-based Cell and Gene Therapies)
Table 25.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 25.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2023-2035
Table 25.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2023-2035
Table 25.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 32.1 Survey Responses: Information on Participating Companies / Organizations
Table 32.2 Survey Responses: Information on Seniority Level of Respondents
Table 32.3 Survey Responses: Information on Type of Manufacturer (In-house Production versus Contract Services)
Table 32.4 Survey Responses: Information on Scale of Operation
Table 32.5 Survey Responses: Information on Type of Vector
Table 34.1 HALIX: Key Highlights
Table 34.2 Batavia Biosciences: Key Highlights
Table 34.3 CEVEC Pharmaceuticals: Key Highlights
Table 34.4 Delphi Genetics: Key Highlights
Table 34.5 Clean Cells: Key Highlights
Table 34.6 Novasep: Key Highlights
Table 34.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 34.8 Massachusetts General Hospital: Key Highlights
Table 34.9 University of Nantes: Key Highlights
Table 34.10 CJ PARTNERS: Key Highlights
Table 34.11 ACGT: Key Highlights
Table 34.12 Polypus Transfection: Key Highlights
Table 34.13 Richter-Helm BioLogics: Key Highlights
Table 34.14 Plasmid Factory: Key Highlights
Table 34.15 Waisman Biomanufacturing: Key Highlights
Table 34.16 EFS-West Biotherapy: Key Highlights
Table 34.17 GEG Tech: Key Highlights
Table 34.18 ViveBiotech: Key Highlights
Table 34.19 Independent Consultant: Key Highlights
Table 35.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 35.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 35.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 35.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 35.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 35.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 35.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Table 35.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 35.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 35.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Table 35.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 35.12 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Table 35.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 35.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 35.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 35.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 35.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 35.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Table 35.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 35.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Region)
Table 35.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Country)
Table 35.22 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 35.23 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 35.24 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 35.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Year of Establishment
Table 35.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 35.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Table 35.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer
Table 35.29 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Table 35.30 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 35.31 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Table 35.32 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 35.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 35.34 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 35.35 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Table 35.36 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector
Table 35.37 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 35.38 Most Active Players: Distribution by Number of Technologies
Table 35.39 Catalent Biologics: Annual Revenues, FY 2018 - 9M FY 2023 (USD Billion)
Table 35.40 Charles River Laboratories: Annual Revenues, FY 2018 - H1 FY 2023 (USD Billion)
Table 35.41 Thermo Fisher Scientific: Annual Revenues, FY 2018 – 9M FY 2023 (USD Billion)
Table 35.42 Lonza: Annual Revenues, FY 2018 – H1 FY 2023 (CHF Billion)
Table 35.43 Wuxi AppTec: Annual Revenues, FY 2018 - H1 FY 2023 (RMB Billion)
Table 35.44 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 35.45 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.46 Partnerships and Collaborations: Distribution by Scale of Operation
Table 35.47 Partnerships and Collaborations: Distribution by Type of Vector Manufactured
Table 35.48 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 35.49 Partnerships and Collaborations: Distribution by Application Area
Table 35.50 Most Active Players: Distribution by Number of Partnerships
Table 35.51 Partnerships and Collaborations: Local and International Agreements
Table 35.52 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 35.53 Recent Expansions: Cumulative Year-wise Trend, 2019-2023
Table 35.54 Recent Expansions: Distribution by Type of Expansion
Table 35.55 Recent Expansions: Distribution by Year and Type of Expansion
Table 35.56 Most Active Players: Distribution by Number of Expansions
Table 35.57 Most Active Players: Distribution by Amount Invested
Table 35.58 Recent Expansions: Distribution by Type of Manufacturing Facility
Table 35.59 Recent Expansions: Distribution by Scale of Operation
Table 35.60 Recent Expansions: Distribution by Type of Vector Manufactured
Table 35.61 Recent Expansions: Distribution by Application Area
Table 35.62 Recent Expansions: Distribution by Location of Expansion
Table 35.63 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Table 35.64 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 35.65 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 35.66 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Operation (in Liters)
Table 35.67 Global Installed Viral Vector Manufacturing Capacity: Distribution by Location of Headquarters (Region) (in Liters)
Table 35.68 Global Installed Viral Vector Manufacturing Capacity: Distribution by Location of Manufacturing Facility (in Liters)
Table 35.69 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 35.70 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 35.71 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation (in Liters)
Table 35.72 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Headquarters (Region) (in Liters)
Table 35.73 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facility (in Liters)
Table 35.74 Global Demand for Viral Vector and Plasmid DNA, 2023-2035 (Thousand Patients)
Table 35.75 Clinical Demand for Viral Vector and Plasmid DNA, 2023-2035 (Thousand Patients)
Table 35.76 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 35.77 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 35.78 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 35.79 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geography (Thousand Patients)
Table 35.80 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Table 35.81 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 35.82 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 35.83 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 35.84 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geography (Thousand Patients)
Table 35.88 Global Viral Vector and Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.89 Global Viral Vector and Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
Table 35.90 Global Viral Vector and Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
Table 35.91 Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.92 Viral Vector and Plasmid DNA Manufacturing Market for Clinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.93 Viral Vector and Plasmid DNA Manufacturing Market for Commercial Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.94 Viral Vector and Plasmid DNA Manufacturing Market for AAV Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.95 Viral Vector and Plasmid DNA Manufacturing Market for Adenoviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.96 Viral Vector and Plasmid DNA Manufacturing Market for Lentiviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.97 Viral Vector and Plasmid DNA Manufacturing Market for Retroviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.98 Viral Vector and Plasmid DNA Manufacturing Market for Plasmid DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.99 Viral Vector and Plasmid DNA Manufacturing Market for Other Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.100 Viral Vector and Plasmid DNA Manufacturing Market for Gene Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.101 Viral Vector and Plasmid DNA Manufacturing Market for Cell Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.102 Viral Vector and Plasmid DNA Manufacturing Market for Vaccine Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.103 Viral Vector and Plasmid DNA Manufacturing Market for Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.104 Viral Vector and Plasmid DNA Manufacturing Market for Rare Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.105 Viral Vector and Plasmid DNA Manufacturing Market for Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.106 Viral Vector and Plasmid DNA Manufacturing Market for Sensory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.107 Viral Vector and Plasmid DNA Manufacturing Market for Metabolic Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.108 Viral Vector and Plasmid DNA Manufacturing Market for Musculoskeletal Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.109 Viral Vector and Plasmid DNA Manufacturing Market for Blood Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.110 Viral Vector and Plasmid DNA Manufacturing Market for Immunological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.111 Viral Vector and Plasmid DNA Manufacturing Market for Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.112 Viral Vector and Plasmid DNA Manufacturing Market for In-house Manufacturers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.113 Viral Vector and Plasmid DNA Manufacturing Market for Contract Manufacturing Organizations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.114 Viral Vector and Plasmid DNA Manufacturing Market in North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.115 Viral Vector and Plasmid DNA Manufacturing Market in Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.116 Viral Vector and Plasmid DNA Manufacturing Market in Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.117 Viral Vector and Plasmid DNA Manufacturing Market in Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.118 Viral Vector and Plasmid DNA Manufacturing Market in Latin America and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Table 35.119 Survey Analysis: Distribution by Seniority Level of Respondents
Table 35.120 Survey Analysis: Distribution by Type of Manufacturer
Table 35.121 Survey Analysis: Distribution by Scale of Operation
Table 35.122 Survey Analysis: Distribution by Type of Vector Manufactured

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 4D Molecular Therapeutics
  2. 53Biologics
  3. AavantiBios
  4. Abbott
  5. AbbVie
  6. Abeona Therapeutics
  7. Abintus Bio
  8. Accinov (acquired by Advanced BioScience Laboratories)
  9. Acucela
  10. AcuraBio
  11. Adaptimmune Therapeutics
  12. AdaptVac
  13. Addgene
  14. Aduro Biotech
  15. Advaccine
  16. Advanced BioScience Laboratories
  17. Advanced Biotherapeutics Consulting
  18. Advantagene
  19. Advaxis
  20. Advent 
  21. Adverum Biotechnologies (formerly known as Avalanche Biotechnologies)
  22. Aevitas Therapeutics (a subsidiary of Fortress Biotech)
  23. AffyImmune Therapeutics
  24. AffyXel
  25. AGC Biologics
  26. Agilent Technologies
  27. Agilis Biotherapeutics (acquired by PTC Therapeutics)
  28. Ajinomoto Bio-Pharma Services
  29. Akdeniz University
  30. Akron Biotech
  31. Albumedix
  32. Aldevron
  33. Allele Biotechnology
  34. Allergan
  35. Allife Medicine
  36. Allogene Therapeutics
  37. Alma Bio Therapeutics
  38. AlphaVax
  39. ALSTEM
  40. Althea Technologies
  41. Altimmune
  42. Altor BioScience
  43. Altruist Biologics
  44. American Gene Technologies
  45. Amgen
  46. Amicus Therapeutics
  47. Ampersand Capital Partners
  48. AMSBIO
  49. Amsterdam BioTherapeutics Unit
  50. Amsterdam Molecular Therapeutics (acquired by uniQure)
  51. Anaeropharma Science
  52. Andelyn Biosciences
  53. Anemocyte
  54. AnGes
  55. Angionetics
  56. ANLBIO
  57. Annapurna Therapeutics (acquired by Avalanche Biotechnologies)
  58. apceth Biopharma (subsidiary of Hitachi Chemical)
  59. Applied Biological Materials
  60. Applied Genetic Technologies (AGTC)
  61. Applied StemCell
  62. Applied Viromics
  63. Arcellx
  64. ArcticZymes Technologies
  65. Areta International
  66. Arranta Bio (acquired by Recipharm)
  67. Aruvant Sciences
  68. ASC Therapeutics
  69. AskBio
  70. Asklepios BioPharmaceutical
  71. Astellas Pharma
  72. AstraZeneca
  73. Atara Biotherapeutics
  74. Atlantic Bio GMP (a subsidiary of Atlanpole Biotherapies)
  75. Atsena Therapeutics
  76. Audentes Therapeutics (acquired by Astella Pharma)
  77. Augusta University
  78. Aurigene Pharmaceutical Services
  79. Aurora Biopharma
  80. Autolus Therapeutics
  81. Avantor
  82. Avecia Biologics
  83. Avid Bioservices
  84. AVROBIO
  85. Axovant Gene Therapies
  86. Bamboo Therapeutics
  87. Batavia Biosciences
  88. Baylor College of Medicine
  89. BCM Families Foundation
  90. Beacon Biotherapeutics
  91. Beam Therapeutics
  92. Beckman Research Institute
  93. Beijing Biohealthcare Biotechnology
  94. Beijing Doing Biomedical
  95. Beijing Hetang Shenghua Medical Technology
  96. Beijing HuiNengAn Biotech
  97. Beijing Immunochina Medical Science & Technology
  98. Beijing Mario Biotech
  99. Beijing Sanwater Biological Technology
  100. Bellicum Pharmaceuticals
  101. Benitec Biopharma
  102. BIA Separations (acquired by Sartorius)
  103. Bioceltech Therapeutics
  104. BioCentriq (acquired by GC)
  105. BioCina
  106. Biogen
  107. Bio-Gene Technology
  108. BioInvent International
  109. Biological E.
  110. BioMarin Pharmaceuticals
  111. Biomay
  112. Biomiga
  113. Bionic Sight
  114. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
  115. Bio-Rad Laboratories
  116. BioReliance (a subsidiary of Merck KGaA)
  117. Bio-Synthesis
  118. BioVec Pharma
  119. Bioverativ
  120. Biovian
  121. BioVision
  122. Blue Sky BioServices (a subsidiary of LakePharma)
  123. bluebird bio (formerly known as Genetix Pharmaceuticals)
  124. BMS
  125. Boehringer Ingelheim BioXcellence
  126. BoYuan RunSheng Pharma
  127. Brain Neurotherapy Bio
  128. Brammer Bio (acquired by Thermo Fisher Scientific)
  129. Brazilian Biosciences National Laboratory (LNBio)
  130. Bristol Myers Squibb
  131. Cabaletta Bio
  132. Caltech
  133. Cambridge Gene Therapy
  134. Candel Therapeutics
  135. Capsugel 
  136. Carina Biotech
  137. Carmine Therapeutics
  138. CARsgen Therapeutics
  139. Cartesian Therapeutics
  140. Casey Eye Institute
  141. Castle Creek Biosciences
  142. Catalent Biologics
  143. Celgene
  144. Cell and Gene Therapy Catapult
  145. Cell Biolabs
  146. Cellectis
  147. CellGenTech
  148. Cellular Biomedicine Group
  149. CellVec
  150. Celonic
  151. Celsion
  152. Celyad Oncology
  153. Center for Breakthrough Medicines
  154. Centre for Commercialization of Regenerative Medicine
  155. Centre for Process Innovation
  156. Cepham Life Sciences
  157. CEVEC Pharmaceuticals
  158. CG Oncology
  159. Charles River Laboratories 
  160. Children’s Medical Research Institute (CMRI)
  161. Children's Hospital of Philadelphia
  162. China Immunotech Biotechnology
  163. Choroideremia Research Foundation
  164. Cincinnati Children's Hospital Medical Center
  165. City of Hope
  166. Clean Cells
  167. CLINO
  168. Cognate BioServices
  169. CoJourney
  170. CombiGene
  171. Copernicus Therapeutics
  172. Cornell University
  173. Creative Biogene
  174. Creative Biolabs
  175. CSL Behring
  176. Curia
  177. Cytiva (formerly known as GE Healthcare Life Sciences)
  178. CytoMed Therapeutics
  179. Cytovance Biologics
  180. Daiichi Sankyo
  181. Decibel
  182. Delphi Genetics
  183. Denali Therapeutics
  184. Department of Cell and Chemical Biology, Leiden University Medical Center
  185. DiNAMIQS
  186. DiNAQOR
  187. DNAtrix
  188. Duke University
  189. Durham
  190. Dyno Therapeutics
  191. Editas Medicine
  192. ElevateBio
  193. Elixirgen Scientific
  194. Emendo Biotherapeutics
  195. Emergent BioSolutions
  196. Emory University School of Medicine
  197. enGene
  198. Epeius Biotechnologies
  199. Errant Gene Therapeutics
  200. Erytech Pharma
  201. Esco Aster
  202. Esteve
  203. eTheRNA immunotherapies
  204. EUFETS
  205. Eureka Biotechnology
  206. Eurofins Genomics
  207. Eurofins Scientific
  208. ExcellGene
  209. Exothera
  210. Expression Therapeutics
  211. Eyevensys
  212. Fate Therapeutics
  213. FerGene
  214. FIMA
  215. FinVector (formerly known as Ark Therapeutics)
  216. Five Prime Therapeutics
  217. Flash Therapeutics
  218. Flexion Therapeutics
  219. Florida Biologix
  220. Forecyte Bio
  221. Forge Biologics
  222. Formula Pharmaceuticals
  223. Fortress Biotech
  224. Fosun Pharma
  225. Foundation Fighting Blindness
  226. Fraunhofer Institute for Toxicology and Experimental Medicine
  227. Freeline Therapeutics
  228. FUJIFILM Diosynth Biotechnologies
  229. Fundamenta Therapeutics
  230. G-CON Manufacturing 
  231. GE Healthcare Life Sciences
  232. GEG Tech
  233. Genable Technologies
  234. GeneCopoeia
  235. GeneCure Biotechnologies
  236. GeneDetect
  237. GeneImmune Biotechnology
  238. Genelux
  239. GeneMedicine
  240. Genenta Science 
  241. GeneOne Life Science
  242. Genethon
  243. GENEWIZ 
  244. Genexine
  245. Genezen Laboratories
  246. GenIbet Biopharmaceuticals
  247. Genopis (acquired by Wacker Biotech)
  248. Genovac
  249. Genprex
  250. GenScript
  251. GenSight Biologics
  252. GenVec
  253. Gen-X
  254. Genzyme
  255. GeoVax Labs
  256. GIGA
  257. GlaxoSmithKline
  258. Gracell Biotechnologies
  259. Gradalis
  260. Green Cross LabCell
  261. Grousbeck Gene Therapy Center
  262. Guangdong Xiangxue Precision Medical Technology
  263. Guangdong Zhaotai InVivo Biomedicine
  264. Guangzhou Anjie Biomedical Technology
  265. Guangzhou FineImmune Biotechnology
  266. Gyroscope Therapeutics
  267. Hadassah Medical Organization
  268. HaemaLogiX
  269. HALIX
  270. Handl Therapeutics
  271. Hanmi Bio Plant (a subsidiary of Hanmi Pharm)
  272. Harvard Gene Therapy Initiative
  273. Hebei Senlang Biotechnology
  274. Heidelberg University Hospital
  275. Helixmith
  276. Hemera Biosciences
  277. Henan Hualong Biotechnology
  278. Herantis Pharma
  279. Hitachi Chemical Advanced Therapeutics Solutions
  280. Holostem Terapie Avanzate
  281. Homology Medicines
  282. Hong Kong Institute of Biotechnology
  283. Hookipa Biotech
  284. HORAMA
  285. Hrain Biotechnology
  286. Huadao biomedical
  287. Huapont Life Sciences
  288. Human Stem Cells Institute 
  289. Hunan Zhaotai Yongren Medical Innovation
  290. Icahn School of Medicine at Mount Sinai
  291. iCAR Bio Therapeutics
  292. iCarTAB BioMed
  293. iCell Gene Therapeutics
  294. ID Pharma (formerly known as DNAVEC)
  295. IDT Biologika
  296. Ilya Pharma
  297. Immatics
  298. Immune Design
  299. Immune Technology
  300. Immunocore
  301. Immunomic Therapeutics
  302. Imperial Innovations
  303. Imperial Innovations 
  304. Indiana University
  305. Innovative Cellular Therapeutics
  306. InnovaVector
  307. INOVIO Pharmaceuticals
  308. InProTher
  309. Institute for Bioengineering of Catalonia
  310. Institute of Medical Science Research Hospital
  311. Institute of Translational Health Sciences
  312. International AIDS Vaccine Initiative (IAVI)
  313. InvivoGen
  314. IPPOX Foundation
  315. IQVIA (formerly known as QuintilesIMS)
  316. Iveric Bio
  317. JAFRAL Biosolutions
  318. Jansen Pharmaceuticals
  319. Jiangsu Puxin Biomedicine
  320. Juno Therapeutics
  321. Juventas Cell Therapy
  322. JW Therapeutics
  323. KAEDI
  324. Kaneka Eurogentec
  325. Karolinska Institute
  326. Karolinska University Hospital
  327. Kavli Institute for Systems Neuroscience
  328. Kecellitics Biotech
  329. King's College London
  330. Kite Pharma (a subsidiary of Gilead Sciences)
  331. KMD Bioscience
  332. Kobe Biomedical Innovation Cluster
  333. Kolon TissueGene
  334. Kriya Therapeutics
  335. Krystal Biotech
  336. Kuur Therapeutics
  337. Laboratory of Digital Sciences of Nantes
  338. LakePharma (acquired by Curia)
  339. Legend Biotech
  340. Leiden University Medical Centre
  341. Lentigen Technology  
  342. Leucid Bio
  343. Leukocare
  344. Leuven Viral Vector Core (LVVC)
  345. Lexeo
  346. LEXEO Therapeutics
  347. Lion TCR
  348. Lipigon Pharmaceuticals
  349. LNBio
  350. LogicBio Therapeutics
  351. LOKA Biosciences
  352. Lokon Pharma
  353. Lonza
  354. Louisiana State University School of Veterinary Medicine
  355. Luina Bio
  356. Luminous BioSciences
  357. Lund University
  358. Lysogene
  359. Magee-Womens Research Institute
  360. Maine Medical Center Research Institute (MMCRI)
  361. MaineHealth Institute for Research
  362. MaineHealth Institute for Research (MHIR)
  363. MangoGen Pharma
  364. Marino Biotechnology
  365. Mass Biologics
  366. Massachusetts Eye and Ear
  367. Massachusetts General Hospital
  368. MassBiologics
  369. Matica Biotechnology
  370. MaxCyte
  371. Mayflower Bioscience
  372. Mayo Clinic Cancer Center
  373. McMaster Immunology Research Centre (MIRC)
  374. MD Anderson Cancer Institute
  375. medac
  376. Medigene
  377. MedImmune
  378. MeiraGTx
  379. Memorial Sloan Kettering Cancer Center
  380. Merck
  381. MicroBiopharm Japan
  382. Microsoft
  383. Mila’s Miracle Foundation
  384. MilliporeSigma
  385. Milo Biotechnology
  386. Miltenyi Biotec
  387. Minerva Biotechnologies
  388. MingJu Therapeutics
  389. Mitsubishi Tanabe Pharma
  390. Moderna
  391. Molecular Diagnostic Services
  392. MolMed (acquired by AGC Biologics)
  393. Momotaro-Gene
  394. MultiVir
  395. Mustang Bio
  396. Mycenax Biotech
  397. Myeloma Crowd
  398. Nanjing Bioheng Biotech
  399. Nantes Gene Therapy Institute
  400. Naobios (a subsidiary of Clean Biologics)
  401. National Cancer Institute
  402. National Center for Advancing Translational Sciences
  403. National Human Genome Research Institute
  404. National Institute of Allergy and Infectious Diseases
  405. National Institute of Environmental Health Sciences
  406. National Institute of Neurodegenerative Disorders and Stroke
  407. Nationwide Children's Hospital
  408. Naval Medical Research Center
  409. Neurimmune
  410. NeuroCure
  411. Neurophth Therapeutics
  412. Neuroscience Center Zurich
  413. New Jersey Innovation Institute (NJII)
  414. NewLink Genetics
  415. NHS Blood and Transplant
  416. Nikon CeLL innovation
  417. Noga therapeutics
  418. Norgen Biotek
  419. Northern RNA
  420. NorthX Biologics
  421. Nouscom
  422. Novartis
  423. Novartis Gene Therapies
  424. Novasep
  425. Novavax
  426. OBiO Technology
  427. Odylia Therapeutics
  428. OHSU Casey Eye Institute
  429. Okairos
  430. Omnia Biologics
  431. OmniaBio
  432. Oncolys BioPharma
  433. OncoSenX
  434. ORCA Therapeutics
  435. Oregon Health & Science University
  436. Orgenesis 
  437. Otonomy
  438. Oxford BioMedica
  439. Oxford Genetics 
  440. OXGENE
  441. OZ Biosciences
  442. PackGene Biotech
  443. PACT Pharma
  444. Pall Biotech
  445. Paragon Bioservices
  446. Paras Biopharmaceuticals
  447. Passage Bio
  448. PeriphaGen
  449. PerkinElmer
  450. PersonGen BioTherapeutics
  451. Peter MacCallum Cancer Centre 
  452. Pfizer
  453. PharmaCell
  454. pHion Therapeutics
  455. PhorMed
  456. Pinze Lifetechnology
  457. PlasmidFactory
  458. Porton Advanced Solutions
  459. Poseida Therapeutics
  460. Precigen
  461. Precision BioSciences
  462. Pregene Biotechnology
  463. Prevail Therapeutics
  464. Prime Vector Technologies
  465. ProBioGen
  466. PROGEN
  467. Progenics Pharmaceuticals
  468. ProMab Biotechnologies
  469. Protheragen
  470. Provecs Medical
  471. PsiOxus Therapeutics
  472. PTC Therapeutics
  473. Puresyn
  474. Quethera (acquired by Astellas Pharma)
  475. RD-Biotech
  476. Regeneron Pharmaceuticals
  477. REGENXBIO
  478. ReiThera
  479. Renova Therapeutics
  480. Rentschler Biopharma
  481. Resilience
  482. Richter-Helm BioLogics
  483. Roche
  484. Rocket Pharmaceuticals
  485. Roswell Park Comprehensive Cancer Center
  486. Rznomics
  487. SAB Technology
  488. SAFC
  489. Saiba Biotech
  490. Salk
  491. Sanford Burnham Prebys
  492. Sangamo Therapeutics
  493. Sanofi
  494. Santen Pharmaceutical
  495. Sarepta Therapeutics
  496. Sartorius Stedim Biotech
  497. Scancell
  498. Scorpius BioManufacturing
  499. Seattle Children's Research Institute (SCRI)
  500. Selecta Biosciences
  501. Sensorion
  502. Senti Biosciences
  503. Servier
  504. Shanghai Biomed-Union Biotechnology
  505. Shanghai Bioray Laboratory
  506. Shanghai Cell Therapy Group
  507. Shanghai GeneChem
  508. Shanghai Longyao Biotechnology
  509. Shanghai PerHum Therapeutics
  510. Shanghai Sunway Biotech
  511. Shanghai Unicar-Therapy Bio-medicine Technology
  512. Shenzhen Binde Biotechnology
  513. Shenzhen Sibiono GeneTech
  514. SignaGen Laboratories
  515. SillaJen
  516. Simcere Pharmaceutical
  517. Sinobioway Cell Therapy
  518. SIRION Biotech 
  519. Skyline Therapeutics
  520. Solid Biosciences
  521. Sorrento Therapeutics
  522. Southern RNA
  523. Spark Therapeutics
  524. SQZ Biotechnologies
  525. St. Jude Children's Research Hospital
  526. Stanford University
  527. Symbiosis Pharmaceutical Services
  528. Synpromics
  529. Synthace
  530. System Biosciences
  531. Takara Bio
  532. Takeda Pharmaceutical
  533. Tamid Bio (a subsidiary of Fortress Biotech)
  534. Targovax
  535. Taysha Gene Therapies
  536. TCR2 Therapeutics
  537. TCRCure Biopharma
  538. tebu-bio
  539. Telethon Institute of Genetics and Medicine (TIGEM)
  540. Terry Fox Laboratory
  541. Tessa Therapeutics
  542. The Beijing Pregene Science and Technology
  543. The Hong Kong Institute of Biotechnology
  544. The Hormel Institute 
  545. The Jackson Laboratory
  546. The Jenner Institute
  547. The Michael J. Fox Foundation 
  548. The Native Antigen Company
  549. The University of Queensland
  550. The University of Tennessee Health Science Center
  551. The Vector Core, University of North Carolina
  552. Themis (acquired by Merck)
  553. TheraBiologics
  554. TheraVectys
  555. Thermo Fisher Scientific
  556. Tianjin Mycure Medical Technology
  557. Timmune Biotech
  558. Tmunity Therapeutics
  559. Tolerion
  560. Touchlight
  561. Transgene
  562. Treadwell Therapeutics
  563. Treeway
  564. TriLink BioTechnologies (a subsidiary of Maravai LifeSciences)
  565. Trizell
  566. Twist Bioscience
  567. TxCell
  568. uBriGene Biosciences
  569. UC Davis
  570. UC San Diego School of Medicine
  571. UK Cystic Fibrosis Gene Therapy Consortium
  572. Ultragenyx Pharmaceutical
  573. uniQure
  574. Univercells
  575. University Hospital Tuebingen
  576. University Medical Center Groningen
  577. University of Adelaide
  578. University of California
  579. University of Eastern Finland
  580. University of Florida
  581. University of Iowa
  582. University of Maryland 
  583. University of Michigan Health
  584. University of Minnesota
  585. University of North Carolina
  586. University of Pennsylvania
  587. University of Pittsburgh
  588. University of South Carolina School of Medicine
  589. University of Southampton
  590. University of Tennessee Health Science Center
  591. University of Tokyo
  592. University of Virginia School of Medicine
  593. Urovant Sciences
  594. USC School of Pharmacy
  595. UT Southwestern Medical Center
  596. Vaccine Manufacturing and Innovation Centre (VMIC)
  597. Vaccitech
  598. VBL Therapeutics
  599. VCN Biosciences
  600. Vectalys
  601. Vector Biolabs
  602. Vector BioMed
  603. VectorBuilder
  604. Vecura
  605. Versiti Blood Research Institute 
  606. VGXI
  607. Vibalogics (acquired by Recipharm)
  608. Vigene Biosciences (acquired by Charles River Laboratories)
  609. Vineti
  610. Viralgen (a subsidiary of Asklepios BioPharmaceutical)
  611. Virapur
  612. ViraQuest
  613. ViroCell Biologics
  614. ViroMed
  615. Virovek
  616. VIVEbiotech
  617. Voyager Therapeutics
  618. VVector Bio
  619. VWR (a subsidiary of Avantor)
  620. Wacker Biotech
  621. Waisman Biomanufacturing
  622. Washington University School of Medicine
  623. Wellington Zhaotai Therapies
  624. WhiteLab Genomics
  625. Wuhan Bio-Raid Biotechnology
  626. Wuhan Sian Medical Technology
  627. WuXi AppTec
  628. Wyvern Pharmaceuticals
  629. Xiangxue Life Sciences
  630. Xpress Biologics
  631. XyloCor Therapeutics
  632. Xyphos Biosciences
  633. Yake Biotechnology
  634. Yonsei University Health System
  635. Yposkesi
  636. Yufan Biotechnologies
  637. Ziopharm Oncolog

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com